  Succinylcholine and Dibucaine Number section { margin-bottom: 20px; } table { border-collapse: collapse; } table, tr, th, td { border: 1px solid black; } th, td { padding: 0px 8px 0px 8px; text-align: left; vertical-align: top; } h3, p, ol.custom-counter, li { margin: 0px; padding: 0px; } .text-red { color: red; } .text-black { color: black; } ul.custom-dash { list-style: none; padding-left: 0; margin: 0; } ul.custom-dash > li { display: flex; align-items: flex-start; } ul.custom-dash > li::before { content: "–"; margin-right: 0.5em; flex-shrink: 0; line-height: 1; } ul.custom-dash > li > \*:not(::before) { flex: 1; } ul.custom-dash > li.no-dash::before { content: ""; width: 1em; margin-right: 0.5em; flex-shrink: 0; } /\* Change the ol style \*/ ol.custom-counter { list-style: none; padding-left: 0; counter-reset: custom calc(var(--start, 1) - 1); } ol.custom-counter li { counter-increment: custom; margin-bottom: 5px; } ol.custom-counter li::before { content: counter(custom) ") "; } /\* This is just for this file \*/ ul.custom-bullet-arrow { list-style: none; padding-left: 0; margin: 0; } ul.custom-bullet-arrow > li { display: flex; align-items: flex-start; } ul.custom-bullet-arrow > li::before { content: "↑"; margin-right: 0.5em; flex-shrink: 0; } ul.custom-bullet-arrow > li.no-arrow::before { content: ""; width: 0.5em; margin-right: 0.5em; flex-shrink: 0; } ul.custom-bullet\_arrow ul { list-style-type: disc; padding-left: 1.5em; margin-top: 0.5em; } img.resized-200 { width: 200px; height: auto; } img.resized-400 { width: 400px; height: auto; } img.resized-600 { width: 600px; height: auto; } .mb-10px { margin-bottom: 10px; } .mb-20px { margin-bottom: 20px; } .mt-10px { margin-top: 10px; } .mt-20px { margin-top: 20px; } .reference-notes { font-size: 11px; } .text-indent-45px { text-indent: 45px; } .text-left { text-align: left; } .text-bold { font-weight: bold; }

### Succinylcholine (SCh) and Dibucaine Number

Relationship between dibucaine number and duration of SCh and Mivacron

| Type of pseudocholinesterase (butyrylcholinesterase) | Genotype | Incidence (literature varies) | Dibucaine number | Duration response to SCh or Mivacron |
| --- | --- | --- | --- | --- |
| Homozygous typical | E1u E1u | Normal | 70-80 | Normal |
| Hetrozygous atypical | E1u E1a | 1: 480 | 50-60 | ↑ 50-100% |
| Homozygous atypical | E1a E1a | 1:3,200 | 20-30 | ↑ 4-8 hours |

Stoelting’s Pharmacology & Physiology in Anesthetic Practice 6th Ed, 2022, p. 316

-   Dibucaine is an amide local anesthetic.
-   The dibucaine number reflects the quality of pseudocholinesterase (PCE) ability to hydrolyze SCh and does NOT measure the quantity of the circulating enzyme.
-   It is also used to diagnose homozygous atypical pseudocholinesterase deficiency indirectly.
-   Some literature will refer PCE to as “butyrylcholinesterase” as they are the same.

Dibucaine numbering system:

1) Typical (normal)

-   When Dibucaine is administered to typical PCE, it inhibits the activity of PCE by 70-80%.
-   Thus, Dibucaine number is 70-80
-   This is a normal typical cholinesterase genotype.
-   There is no prolongation of muscle relaxation.

2) Heterozygous:

-   When Dibucaine is administered to a heterozygous individual with an atypical genotype, it inhibits the activity of PCE by 50-100%.
-   Thus, the Dibucaine number is 50-60.
-   This is usually clinically insignificant.
-   Muscle relaxation from succinylcholine or mivacron will be prolonged by seconds to minutes if at all.
-   Literature varies on duration, as it is patient-dependent.
-   1:480 people (literature greatly varies)

3) Homozygous:

-   When Dibucaine is administered to an individual with homozygous atypical genotype, it inhibits activity of PCE by ≤ 30%.
-   Thus, the Dibucaine number is ≤ 30.
-   This is clinically significant.
-   Muscle relaxation from succinylcholine or mivacron will be prolonged by 4-8 hours.
-   Literature varies on duration as it is patient-dependent.
-   1:3,500 people

Refer to _“Succinylcholine - Pseudocholinesterase Deficiency”_ for more information.

Stoelting’s Pharmacology & Physiology in Anesthetic Practice 6th Ed, 2022

CH. 12 Neuromuscular-Blocking Drugs and Reversal Agents, pp. 316-317

Pamela Flood, James P. Rathmell

Prolonged Neuromuscular Blockade Following Succinylcholine Administration to a Patient with a Reduced Butyrylcholinesterase Activity

Case Reports Medicine, June 17;2010

Accessed 09/2025

Ivo F Panhuizen 1,\*, Marc M J Snoeck 1, Soledad Levano 2, Thierry Girard 2

https://pmc.ncbi.nlm.nih.gov/articles/PMC2892671/#:~:text=Genetic%20variants%20of%20butyrylcholinesterase%20result,by%20external%20(nongenetic)%20factors.

Dibucaine Number

The 5-Minute Anesthesia Consult pp. 334, By Benjamin Abraham

Nina Singh-Radcliff